Treace Medical Concepts Inc. (TMCI)
NASDAQ: TMCIHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TMCI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $282.56M
- EPS (TTM)
- -$0.85
- Dividend yield
- None
- 52-week range
- 1.17 – 5.44
- Day range
- 4.17 – 4.43
- Volume / Avg
- 232.75K / 267.11K
- Beta
- —
- Shares outstanding
- 65.56M
52-week range
TMCI stock today
Treace Medical Concepts (TMCI) closed at $4.31 on Nov 20, down 0.92% (-$0.04), versus the S&P 500's 3.70% decline. Shares are 20.8% below their 52-week high of $5.44, set on Nov 11, 2026 and 268.4% above the 52-week low of $1.17, in the middle of the past year's range. TMCI is up 75.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.7%.
Treace Medical Concepts has posted a net loss over the last twelve months (EPS of -$0.85), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Treace Medical Concepts
Company profileTreace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. John T. Treace
- Headquarters
- Ponte Vedra, FL
- Employees
- 450
- IPO year
- 2021
- Website
- treace.com
Financial highlights
Full financialsIn fiscal 2025, Treace Medical Concepts generated $212.7 million in revenue, up 1.6% from fiscal 2024, its 6th consecutive year of revenue growth. Treace Medical Concepts reported a net loss of $59.0 million, compared with a loss of $55.7 million a year earlier. Gross margin was 79.8% (down from 80.4%) and operating margin -25.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $212.69M | $209.36M | $187.12M | $141.84M | $94.42M |
| Growth | +1.59% | +11.89% | +31.92% | +50.22% | +64.59% |
| Net income | $-59.00M | $-55.74M | $-49.53M | $-42.81M | $-20.55M |
| EPS (diluted) | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$6.17+43.16%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-0.19 vs $-0.26
- Surprise
- +26.92%
TMCI news
All TMCI news- Treace Medical Concepts, Inc Q3 Loss NarrowsNasdaq
- Treace Medical Concepts Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction SystemGlobeNewswire
- Treace to Report Third Quarter 2026 Financial Results on November 6, 2026GlobeNewswire
Treace Medical Concepts peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs TMCI |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs TMCI |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs TMCI |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs TMCI |
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs TMCI |
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs TMCI |
| EMBCEmbecta Corp. | 6.02 | -2.75% | $341.09M | vs TMCI |
| BWAYBrainsWay Ltd. ADR | 8.48 | -2.86% | $341.35M | vs TMCI |
Indexes, lists and sector
Treace Medical Concepts stock FAQ
What is Treace Medical Concepts's stock price today?
TMCI last traded at $4.31 as of Nov 20, 4:00 PM EST, down 0.92% on the day. Prices are delayed at least 15 minutes.
Who is Treace Medical Concepts's CEO?
Mr. John T. Treace is the chief executive officer of Treace Medical Concepts Inc., which has about 450 employees.
What is the TMCI 52-week high?
The 52-week high for TMCI is $5.44 and the 52-week low is $1.17. The stock is currently 20.8% below its high.